Prion-like proteins sequester and suppress the toxicity of huntingtin exon 1 by Hesse, William R. et al.
Prion-like proteins sequester and suppress the toxicity
of huntingtin exon 1
Can Kayatekina,1, Kent E. S. Matlacka,1, William R. Hessea,b, Yinghua Guanc,d, Sohini Chakraborteea, Jenny Russe,2,
Erich E. Wankere, Jagesh V. Shahc,d, and Susan Lindquista,f,g,3
aWhitehead Institute for Biomedical Research, Cambridge, MA 02142; bDepartment of Biological Engineering, Massachusetts Institute of Technology,
Cambridge, MA 02139; cDepartment of Systems Biology, Harvard Medical School, Boston, MA 02115; dRenal Division, Brigham and Women’s Hospital, Boston,
MA 02115; eMax Delbrück Center for Molecular Medicine, 13125 Berlin, Germany; and fDepartment of Biology and gHoward Hughes Medical Institute,
Massachusetts Institute of Technology, Cambridge, MA 02139
Contributed by Susan Lindquist, July 3, 2014 (sent for review May 8, 2014)
Expansions of preexisting polyglutamine (polyQ) tracts in at least
nine different proteins cause devastating neurodegenerative
diseases. There are many unique features to these pathologies,
but there must also be unifying mechanisms underlying polyQ
toxicity. Using a polyQ-expanded fragment of huntingtin exon-1
(Htt103Q), the causal protein in Huntington disease, we and others
have created tractable models for investigating polyQ toxicity in
yeast cells. These models recapitulate key pathological features of
human diseases and provide access to an unrivalled genetic
toolbox. To identify toxicity modifiers, we performed an unbiased
overexpression screen of virtually every protein encoded by the
yeast genome. Surprisingly, there was no overlap between our
modifiers and those from a conceptually identical screen reported
recently, a discrepancy we attribute to an artifact of their over-
expression plasmid. The suppressors of Htt103Q toxicity recovered
in our screen were strongly enriched for glutamine- and aspara-
gine-rich prion-like proteins. Separated from the rest of the
protein, the prion-like sequences of these proteins were them-
selves potent suppressors of polyQ-expanded huntingtin exon-1
toxicity, in both yeast and human cells. Replacing the glutamines
in these sequences with asparagines abolished suppression and
converted them to enhancers of toxicity. Replacing asparagines
with glutamines created stronger suppressors. The suppressors
(but not the enhancers) coaggregated with Htt103Q, forming large
foci at the insoluble protein deposit in which proteins were highly
immobile. Cells possessing foci had fewer (if any) small diffusible
oligomers of Htt103Q. Until such foci were lost, cells were
protected from death. We discuss the therapeutic implications of
these findings.
protein misfolding | prions
Protein misfolding and aggregation underlie many neurode-generative diseases. The causes of protein misfolding are
numerous and include single amino acid changes and expansions
of amino acid repeats. Polyglutamine (polyQ) expansions are an
infamous example of the latter and are responsible for at least
nine neurodegenerative conditions, including Huntington dis-
ease (HD). In most of these diseases the polyQ-expanded pro-
tein is expressed throughout the body, but tissue damage is
restricted to the nervous system and, often, to a subset of cells
depending on the causal protein. Thus, there are important cell
type-specific determinants of toxicity, and these are specific to
particular proteins.
Despite these differences, disease severity is tightly linked to
the number of glutamines. Progressively earlier onset occurs as
the number of glutamines increases beyond a critical threshold of
∼35–45 residues (1). Moreover, in all cases, pathology is asso-
ciated with misfolded forms of the polyQ-expanded protein.
Thus, common features that arise from the expansions and result
from shared aspects of polyQ-driven protein misfolding must
contribute to pathology. Given the diverse nature of both the
proteins bearing the polyQ tract and the pathologies they cause,
understanding the nature of the interaction between misfolded
polyQ-expanded proteins and the cellular environment is
a complex but critical area of research.
The most prevalent polyQ disease, HD, is caused by an ex-
pansion of the polyQ tract in the protein huntingtin (Htt). A
fragment of polyQ-expanded Htt, roughly encompassing exon 1
and including the polyQ tract, characteristically aggregates and
accumulates in the cortex and striatum, the regions most sensi-
tive to degeneration in HD (1, 2). The expanded polyQ tract
promotes aberrant splicing of HTT exon 1 and results in the
production of an exon 1 fragment of Htt protein (3). Over-
expression of an exon 1 fragment alone is sufficient to cause
neurodegeneration in mice (4) and is the basis for polyQ toxicity
models in many other organisms, including yeast.
Neuron-specific vulnerabilities cannot be addressed in yeast
models. However, these simple cells possess many archetypal
aspects of protein homeostasis and other fundamental cell bi-
ology that are central to eukaryotes and are known points of
susceptibility in neurodegenerative diseases. These include the
full suite of eukaryotic chaperones and protein remodeling fac-
tors, the ubiquitin/proteasome system, autophagy, vesicle traf-
ficking and the secretory pathway, the nuclear envelope and
chromatin structure, and mitochondrial biology. The relationship
between the length and toxicity of the polyQ region observed in
human diseases is recapitulated in yeast, providing a strong in-
dication that some aspects of polyQ toxicity are conserved (5).
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Generally, polyQ-expanded proteins have altered protein–
protein interactions, which either buffer or propagate the dele-
terious conformational changes of the polyQ-containing protein
(6–11). However, the characteristics that distinguish beneficial
from toxic interactions at a molecular level remain enigmatic.
Taking advantage of the genetic tools available in yeast, we
performed a genome-wide overexpression screen for modifiers
of polyQ toxicity. Of the 5,532 proteins we tested, 10 were highly
reproducible suppressors. These proteins were disparate in their
physiological functions, yet seven of them contained segments of
primary sequence that were enriched for asparagine and gluta-
mine residues (N and Q) and had prion-like character (12).
Prion-like domains in several other proteins have recently been
implicated in many neurodegenerative diseases, raising interest
in these unusual polypeptides (13). We used a variety of cell-
based assays to investigate how prion-like domains can suppress
or enhance the toxicity of polyQ-expanded Htt exon-1.
Results
Prion Domains Recovered from Genome-Wide Screen for Htt103Q
Toxicity Modifiers. To model polyQ-expanded proteotoxicity in
yeast, we created a diploid strain carrying two chromosomally
integrated polyQ-expanded fragment of huntingtin exon-1
(Htt103Q) genes (encoding a FLAG tag, the first 17 amino acids
of Htt, 103 repeats of glutamine, and a fluorescent protein)
under control of the galactose-inducible promoter. This resulted
in an intermediate level of Htt103Q toxicity and enabled us to
screen for both suppressors and enhancers (Fig. 1A). Our ORF
library covered 95% of the proteins encoded by the yeast genome.
Each ORF encoded the protein without either N- or C-terminal
additions and was borne on a single-copy plasmid under the control
of the same galactose-inducible promoter as Htt103Q (14). The
growth of each strain was compared with an Htt103Q strain car-
rying the same plasmid lacking an insert. An ORF was deemed to
be a suppressor or enhancer if it affected growth of the Htt103Q-
expressing strain but not a control strain without Htt103Q.
We identified ten genes that suppressed Htt103Q toxicity (Fig.
1A). (All genes that enhanced Htt103Q toxicity were also toxic in
the control strain lacking Htt103Q and were not further in-
vestigated.) No single cellular process logically connected all of
the proteins. However, inspection of the amino acid sequences of
the suppressors revealed in many a region strongly enriched for
glutamine- and asparagine-rich prion-like sequences. This find-
ing was surprising because other proteins with such domains are
implicated in the pathology of various neurodegenerative dis-
eases (13) and not in protection against proteotoxicity.
In yeast, an individual domain confers the prion characteristics
of most prion proteins. These prion domains (PrDs), both on
their own and in the context of the full-length proteins, are ca-
pable of self-perpetuating conformational changes and can exist
in either soluble or aggregated states (15). To date, over 25
proteins that possess prion-like characteristics have been iden-
tified in yeast, and most of their PrDs are highly enriched for the
amino acids glutamine (Q) and asparagine (N). Many of these
were identified by computational algorithms for ranking the
likelihood that a given protein might function as a prion (12). In
this ranking, seven of our Htt103Q toxicity suppressors (all but
Mbp1, Bre5, and Ykr075c) reside within the top 150 of all pro-
teins in the yeast genome. The likelihood that this occurred by
chance is less than 1 in 1010 (hypergeometric distribution).
Reconciling Different Results from a Similar Screen. Very recently,
an apparently similar yeast overexpression screen for modifiers
of Htt103Q toxicity was reported (16). Of the 317 hits reported,
none were among our suppressors, nor was there a bias for
proteins containing prion-like sequences. We investigated three
properties of the Mason et al. (16) screen that differed from our
own and might account for the disparate findings: (i) a haploid
yeast strain from a different genetic background was used; (ii)
each ORF carried three C-terminal tags, HA, 6x His, and protein
A; and (iii) both the Htt103Q expression construct and the ORF
library were on high-copy 2μ plasmids. After reanalyzing their
strongest suppressor, Gpx1, in a variety of strains (Fig. S1 and SI
Results), we concluded that their suppressors were recovered due
to an artifact of using two high-copy plasmids that both carried
the galactose-regulated promoter (for the expression of both
Htt103Q and the ORF library). Using a 2μ to express the ORF
will create competition for limiting transcription factors and re-
duce the expression of Htt103Q. The variations in copy number
that occur with 2μ libraries likely accounted for the apparent
differences in suppression. We also note that while our manu-
script was under review, another overexpression screen for
modifiers of Htt103Q toxicity in yeast reported results highly
consistent with our own (17).
PrDs Themselves Can Suppress Htt103Q Toxicity. The high percent-
age of proteins containing prion-like domains among our sup-
pressors prompted us to examine whether the Q/N-rich PrDs
might suppress toxicity on their own. First, we tested the PrD
segments from four of the suppressors identified in our screen—
Nup49, Pop2, Sup35, and Gts1 (see ref. 12 for the amino acid
sequences of all PrDs), each expressed with a C-terminal EYFP
fusion. Overexpression of just the PrDs of Nup49 and Pop2 did
not suppress Htt103Q toxicity, indicating that it is not just
Q-richness that determines suppression. It may be that the full-
length protein or a longer fragment of the protein is required.
[While our paper was under review, a slightly longer fragment of
Pop2 was reported to suppress Htt103Q toxicity (17).] More
importantly, the PrDs of both Sup35 (known as NM) and Gts1
were effective suppressors, demonstrating that some PrDs can
modify Htt103Q toxicity on their own.
Next, we tested 38 previously reported N- or Q-rich PrDs
(Table S1) (12). Of 20 Q-rich PrDs tested, 12 suppressed
Htt103Q toxicity, whereas only 2 of 22 N-rich PrDs were capable
of suppression. Both N-rich PrD suppressors also possessed
Q-rich segments.
To more rigorously test the relationship between the sup-
pression of toxicity and the enrichment for Q/N residues, we
used two sets of PrD variants (Table S2). In one set, all gluta-
mine residues were changed to asparagines (Q→N). In the sec-
ond set, all asparagine residues were changed to glutamines
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Fig. 1. Overexpression screen for modifiers of Htt103Q toxicity in yeast. (A)
An example plate with (Left) representative suppressor (S) and enhancer (E)
hits and (Right) the 10 confirmed hits in duplicate along with uninduced and
neutral controls (EYFP). Hits with PrDs are marked with an asterisk. (B)
Growth of cells expressing Htt103Q and PrD modifiers or PrD variants where
asparagines were replaced with glutamine (N→Q) or where glutamines were
replaced with asparagine (Q→N). Suppressors are shown in blue, and
enhancers are shown in orange. (C) High-content microscopy analysis of
SH-EP cells coexpressing Htt79Q and PrD modifiers. GIT1 (black) and PFN1 (light
gray) are aggregation-enhancing and aggregation-suppressing controls,
respectively. (D) Cell death and aggregation in HEK-293 cells coexpressing
Htt72Q and PrD suppressors. Only the PrDs with high expression in this cell
line were used for this analysis. *P < 0.05, **P < 0.01, and ***P < 0.001.
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(N→Q). Each of the N→Q variants potently suppressed
Htt103Q toxicity. In fact, the N→Q variants were much more
potent than the wild-type PrDs and were stronger than any of the
suppressors identified in the screen. The Q→N variants not only
failed to suppress toxicity but in contrast often enhanced it (Fig.
1B and Fig. S2).
PrDs Can Also Reduce Htt Toxicity in Human Cells. The neurode-
generation caused by various polyQ expansion proteins is highly
cell specific, despite the fact that these proteins are broadly
expressed throughout the body. Thus, toxicity in any particular
cell type must be influenced by the sequences flanking the polyQ
segments and the unique proteomes of the susceptible cell types
(5, 18, 19). We do not, therefore, suggest that our yeast sup-
pressors are directly relevant to human disease. Nor would we
expect them to behave in any particular mammalian cell type ex-
actly as they do in yeast or another mammalian cell type. Rather,
we consider them “proteome-modifying agents” and wondered if
some of them are capable of modifying the aggregation and/or
toxicity of polyQ-expanded Htt exon-1 in any human cell type.
First, we used a neuroblastoma-derived cell line (SH-EP)
where the expression of polyQ expansion proteins is not toxic
and examined changes in the aggregation state of Htt (20). We
chose to limit this analysis to the prion domains in which we had
exchanged all of the Qs or all of the Ns because these produced
the strongest phenotypes. Cell cultures were cotransfected with
Htt79Q (tagged with YFP) and our PrD modifiers (tagged with
mCherry). The aggregation of Htt79Q in cells that expressed
both proteins was scored 48 h posttransfection, using high-con-
tent fluorescence microscopy and an automated imaging system.
This instrument assesses the mean intensity, area, and number of
aggregates per cell, normalized to a neutral control (beta-glu-
curonidase from Escherichia coli, uidA). Two human proteins
lacking PrDs—the GIT1 protein, which increases polyQ-
expanded Htt exon-1 aggregation, and the PFN2 protein, which
decreases it (21, 22)—were used as additional controls. In this
cell line, the N-rich PrDs increased aggregation of Htt79Q,
whereas most of the Q-rich variants had the opposite effect (Fig.
1C and Fig. S3).
To examine cells with a different tissue of origin and hence
a different proteome, we used HEK293 cells. These cells are
commonly used to study both the toxicity and aggregation of
various disease-related proteins (23). We cotransfected cells with
Htt72Q (tagged with GFP) and several of the yeast PrD modi-
fiers (tagged with mCherry). After 48 h, we fixed the cells and
scored them for aggregation of Htt72Q and cell death (Fig.
1D and Fig. S4). Only four of the PrDs were expressed at sufficient
levels to include in the analysis (NM, NMN→Q, Ure2N→Q, and
Gal11). The effects of these proteins on Htt72Q aggregation
varied. NM had no visible effect, NMN→Q significantly decreased
aggregation, and Gal11 and Ure2N→Q increased aggregation.
Nevertheless, all four of these Q-rich PrDs suppressed Htt72Q
toxicity. NM and Ure2N→Q reduced cell death by over 40%,
whereas NMN→Q and Gal11 attenuated toxicity by ∼20%. Al-
though we neither expected nor found identical outcomes in the
two different human cell types and in yeast, clearly, the PrD
modifiers can affect both the aggregation and the toxicity of
polyQ-expanded Htt exon-1 in the context of human proteomes.
Paradoxically, PrD Suppressors Increase Htt103Q Protein Levels. To
investigate further, we returned to the more tractable yeast cells.
These cells provide genetically identical, genomically stable pop-
ulations that are subject to only minor epigenetic modifications of
gene activity in culture. Further, each and every cell carries an
identical complement of inducible genes, either integrated in the
genome or on a plasmid. This ensures more homogenous and
controlled gene expression across the entire population.
We first asked if coexpression of PrD modifiers altered the
amount of Htt103Q protein in the yeast cells. Western blotting
with antibodies against GFP simultaneously revealed the Htt103Q
protein and the PrD modifiers because both were modified with
a GFP variant (Fig. 2A). Enhancers did not increase the level of
Htt103Q protein (if anything, they decreased it). Even more sur-
prisingly, suppressors of Htt103Q toxicity actually increased
Htt103Q protein levels (Fig. 2A). Experiments in which cyclo-
heximide was used to abruptly terminate all protein synthesis
demonstrated that the half-life of the Htt103Q was dramatically
increased by the presence of a PrD suppressor (Fig. 2B). Because
coexpression of PrD suppressors does not decrease the amount of
Htt103Q, they must (directly or indirectly) reduce its toxicity.
PrD Suppressors Form Large Coaggregates with Htt103Q.We turned
to fluorescence microscopy to examine the relative localization
of Htt103Q and the PrD modifiers in the yeast cells. In the ab-
sence of a modifier, the toxic Htt103Q protein formed irregular
agglomerations of various sizes and shapes distributed through-
out the cytoplasm (Fig. 3A). As expected, a coexpressed EYFP
control (EYFP protein alone) was diffusely distributed in these
cells. When cells coexpressed EYFP-tagged enhancers, the ag-
gregation pattern of Htt103Q did not change in any obvious way,
and the enhancer protein either remained diffuse or formed
independent aggregates that excluded Htt103Q. In the presence
of a suppressor, however, Htt103Q collected in only one or two
large foci in the cytoplasm of each cell, where it colocalized with
the suppressor protein (Fig. 3A and Fig. S5).
Cells with Suppressor/PrD Coaggregates Grow More Rapidly. To
determine whether the formation of large Htt103Q foci was di-
rectly related to the suppression of toxicity, we used a PrD with
only moderate suppressor activity (NM) and which colocalized
with Htt103Q in many but not all cells. Time-lapse video mi-
croscopy of yeast in microfluidic chambers allowed us to both
monitor protein aggregation within each cell and unambiguously
track the lineages of the cells as they divided over the course of
the experiment. Thus, any difference in the growth rates of cells
with and without aggregates would be apparent.
As expected, some founder cells possessed colocalized foci of
NM and Htt103Q. In others, the foci contained only Htt103Q
but not the suppressor. As the colonies grew, cells descended
from founders with colocalized foci often maintained that dis-
tribution and repeatedly divided, eventually taking over the en-
tire field of view. Cells in which NM was not colocalized with
Htt103Q grew poorly and soon died (Fig. 3B). Cells that initially
possessed both colocalized and independent Htt103Q aggregates
were particularly informative. In these, the focus in which NM
and Htt103Q colocalized was occasionally lost. When this hap-
pened, it was quickly followed by cell death (Fig. 3C). In total,
cells that did not inherit a colocalized focus (40% of deaths) and
those that lost it (29% of deaths) constituted 69% of deaths.
Suppressor PrD/Htt103Q Coaggregates Accumulate at the IPOD. In
eukaryotes, there are two cytoplasmic sites for the deposition of
misfolded proteins: the insoluble protein deposit (IPOD) and the
juxtanuclear quality control compartment (JUNQ) (24). The
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Fig. 2. Effect of PrD suppressors on Htt103Q protein levels. (A) Western blot
for EGFP and Pgk1 reveals the protein levels of Htt103Q, the modifier, and
Pgk1 (loading control) in cells grown overnight in 2% galactose. Bands
corresponding to modifiers are marked with asterisks. (B) Htt103Q protein
levels in cells expressing the suppressor NMN→Q (blue line) or a neutral
protein (EYFP, gray line) as a function of time following inhibition of
translation with cycloheximide.
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IPOD is located near the vacuole and serves as a site for the
sequestration of aggregated proteins. The JUNQ is located ad-
jacent to the nucleus and contains misfolded proteins that are
destined for proteasomal degradation. To test whether Htt103Q
localizes to either of these structures, we coexpressed Htt103Q
and some of our PrD modifiers in three separate yeast strains
carrying markers for different subcellular compartments.
These labeled either the IPOD with Rnq1, the JUNQ with von
Hippel-Lindau tumor suppressor (VHL), or the nucleus with
NHP6a. Htt103Q formed many small puncta when expressed on
its own or together with an enhancer. These aggregates were
broadly distributed and often around, but not within, the nucleus.
In the majority of cells (82 ± 9%), a small portion of Htt103Q was
colocalized with VHL at the JUNQ (Fig. S6). However, much of
the aggregated Htt103Q was outside the JUNQ and never lo-
calized to the IPOD (Fig. 4). In contrast, when Htt103Q was
coexpressed with a suppressor PrD, both proteins consistently
colocalized at the IPOD (Fig. 4).
Proteins localized to the IPOD characteristically have very
low mobility (24). To determine if Htt103Q and suppressor
proteins in the IPOD had these dynamics, we used fluorescence
recovery after photobleaching (FRAP) to quantify the mobility
of Htt103Q molecules inside and outside the foci. We photo-
bleached a small region of the cell with a brief, intense laser
pulse and then determined how quickly fluorescence was re-
stored by the migration of unaffected proteins into this spot. In
cells coexpressing Htt103Q and NM, photobleached regions
outside of foci regained roughly 60% of their signal within a
minute and eventually recovered more than 80% of their original
fluorescence, indicating that the Htt103Q molecules outside of
foci were highly mobile. In contrast, when we photobleached
Htt103Q protein inside foci, recovery was negligible for at least
5 min (Fig. 5A). Thus, Htt protein localized to the IPOD is
highly immobile.
PrD Suppressors Eliminate Diffusible Oligomers of Htt103Q. Small
oligomers have been implicated as the causal agents in many
proteinopathies. To monitor changes in the population of
Htt103Q oligomers caused by our PrD enhancers and sup-
pressors in yeast, we used fluorescence correlation spectroscopy
(FCS) (25). To concentrate our analysis on the Htt103Q protein
that was not localized to large aggregates, cell lysates were
subjected to centrifugation to remove them. The supernatant was
recovered and two-photon excitation was exploited to generate
a very small excitation volume. We measured the fluctuations of
fluorescence caused by the diffusion of single particles into, and
out of, this volume. The brightness of these events (i.e., the
number of fluorophores per diffusing particle) provides a mea-
sure of the oligomerization state of the Htt103Q. To limit arti-
facts from intermolecular quenching, which would result in lower
fluorescence, we used mCherry tags on the PrD modifiers. We
also measured the fluorescence intensity of the lysates to ensure
that the number of fluorophores in the excitation volume was
within acceptable limits. Because some cultures expressing
moderate suppressors contained a mixed population of cells
experiencing varying degrees of toxicity (see above for the ex-
ample of NM), they were excluded from the analysis.
In lysates of cells expressing Htt103Q and a neutral protein
(EYFP), we detected slowly diffusing particles of ECFP-tagged
Htt103Q. The molecular brightness of these particles was much
greater than monomeric fluorophores (i.e., that of ECFP without
Htt103Q), consistent with an oligomeric species (Fig. 5B). In
lysates of cells coexpressing Htt103Q and PrD enhancers, Htt
particles had diffusion coefficients similar to those of cells
expressing Htt103Q and the neutral control (Fig. S7). As de-
termined by their molecular brightness, these particles were
smaller on average but more broadly distributed in sizes. In
lysates of cells coexpressing strong suppressors, Htt103Q par-
ticles had the fastest diffusion coefficients and molecular
brightness comparable to that of monomeric fluorophores, in-
dicating that Htt103Q was monomeric.
Discussion
Starting with an unbiased genome-wide screen, we discovered
that glutamine (Q)-rich protein domains can act as potent sup-
pressors of Htt103Q toxicity. These suppressors coaggregated
with Htt103Q. The resulting Htt103Q aggregates were much less
toxic, and small oligomers of Htt103Q were undetectable. Thus,
interactions between polyQ-expanded disease proteins and other
Q-rich proteins do not always contribute to pathology. Some of
these interactions may instead have the beneficial effect of
capturing the misfolded polyQ-expanded protein and preventing
it from inactivating more essential proteins. The complexities
such interactions are formidable, but understanding them may
offer new therapeutic strategies.
What features of Q-rich domains might determine their ca-
pacity to suppress Htt103Q toxicity? Strikingly, this ability is
inversely related to their capacity to form prions. Prion proteins
have the unusual ability to convert into self-perpetuating amy-
loids, which can act as protein-based elements of inheritance
(15). The majority of known prion proteins have a distinct prion-
determining region (PrD) that is rich in N and Q residues. In
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Fig. 3. PrD suppressors alter the intracellular localization of Htt103Q. (A)
Strains expressing Htt103Q (green) along with a neutral control (EYFP) or an
EYFP-tagged PrD enhancer of toxicity (NMQ→N, red) or an EYFP-tagged
suppressor of toxicity (NMN→Q, red). Far right graph shows quantitation of
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course of a single microcolony coexpressing Htt103Q and NM. (C) The fate of
the cell indicated by the black arrow in B is shown in greater time resolution.
The white arrow indicates the location of a focus with colocalized Htt103Q
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14.5 h, after which the cell died. (All scale bars: 5 μm.)
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in the IPOD. (All scale bars: 5 μm.)
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a previous study unrelated to Htt toxicity, we investigated the
consequences of altering the balance between these two amino
acids (26). PrD variants in which all Q residues were replaced
with N residues were much more likely to convert to the prion,
amyloid form. In the present study, these variants enhanced the
toxicity of Htt103Q. Variants in which all N residues were
replaced with Q residues virtually never converted to the prion
form. These variants suppressed the toxicity of Htt103Q.
Examining the properties of these proteins in vitro, we pre-
viously showed that Q→N PrDs efficiently self-assembled and
formed highly stable amyloids, whereas N→Q variants aggre-
gated much more slowly and rarely formed stable amyloids.
When we tested the capacity of the aggregates formed by these
PrD variants to seed the assembly of themselves and each other,
only N→Q variants (which we identified as suppressors here)
were effective in cross-seeding other sequences. Although these
cross-seeded aggregates are often β-sheet–rich amyloids, Q/N-
rich proteins can also form coiled coils (27). Cross-seeding by
Q-rich PrDs could produce α-helical structures, especially when
coaggregating with another protein that has α-helical propensity,
such as polyQ-expanded Htt exon-1 (28). Although we do not yet
know the structural details of the coaggregates, we suggest that
the capacity of Q-rich PrDs to suppress Htt103Q toxicity is
a direct consequence of their cross-seeding activity.
The large foci formed by coaggregated Htt103Q and the PrD
suppressors resemble the inclusion bodies (IBs) found in the
nervous system of human patients with HD. These foci and IBs
may have similar biological roles. Although IBs were originally
considered to be toxic, a growing compendium of findings sup-
ports a major reinterpretation, that IBs are protective (29). In
support of this interpretation, IB formation often does not cor-
relate with toxicity in yeast, fly, worm, and mouse models of
polyQ toxicity (5, 30–32). In humans with HD, IBs are more
commonly found in regions of the brain that are less affected by
the disease and in less vulnerable cell types (33, 34). Long-term
imaging and survival analysis of neuronal cultures expressing
polyQ-expanded Htt provided a particularly strong argument for
the protective nature of IBs, demonstrating that neurons that
formed IBs survived longer than those that did not (35).
Our yeast PrD modifiers provided a unique opportunity to
directly study the connection between toxicity and aggregation.
Whether coexpressed with a neutral protein, an enhancer, or
a suppressor, a portion of Htt103Q protein was always in an
aggregated state. However, the different forms of aggregates
elicited profoundly different toxicities. Toxic Htt103Q aggre-
gates consisted of many small puncta, whereas protective
Htt103Q aggregates consisted of large foci at the IPOD. In an-
other report, the sequestration of Htt103Q into Sti1 foci, a jux-
tanuclear site distinct from the JUNQ and IPOD, also reduced
toxicity (36). Thus, irrespective of their subcellular localization,
the formation of large Htt103Q foci seems to be protective
against toxicity.
As evidence for the protective nature of IBs has mounted,
a consensus has emerged implicating small oligomeric particles
as the toxic species. For polyQ-containing proteins, oligomers
form before IBs, their formation is polyQ length-dependent, and
their presence is well correlated with cell death (25, 37). Both
chaperones that remodel oligomers and peptides that inhibit
oligomer formation suppress toxicity (38, 39). In our yeast
model, cells experiencing the greatest toxicity harbored many
small oligomers. In cells experiencing the lowest toxicity, similar
oligomers were undetectable. Because the suppressors greatly
increased the total accumulation of Htt103Q, our PrD sup-
pressors must prevent the formation of oligomers and/or pro-
mote their sequestration. PolyQ-expanded Htt exon-1, in vitro,
forms an α-helical oligomer early in the aggregation process (40).
It is possible that the suppressor PrDs intercalate into such
α-helix–rich oligomers and promote their assembly into the large
coaggregated foci.
When overexpressed separately from the rest of the protein,
the PrDs of some of the suppressors recovered from our screen
could not suppress Htt103Q toxicity. In some cases, the PrD and
at least part of the rest of the protein must work together to
relieve Htt103Q toxicity. It is notable that four of these partic-
ular suppressors—Sis1, Nup49, Bre5, and Upb3—fit logically
into a nuclear trafficking and degradation pathway recently
identified in yeast and implicated in Htt103Q toxicity (41, 42). In
previous literature, most Q-rich proteins that modify Htt toxicity
have been shown to be enhancers (7, 8, 10). Indeed, many of the
PrDs we tested that had very strong suppressor activity on their
own were not recovered as suppressors in our screen of the full-
length proteins. The Q-rich segments, as well as the rest of the
protein to which they are attached, can each influence Htt toxicity
and can do so in different ways. Thus, the physical interaction of
Q-rich PrDs with Htt103Q, although highly significant, is not the
sole determinant of toxicity suppression or enhancement.
The interaction between Q-rich PrDs and the polyQ-expanded
disease protein is not necessarily specific to a given cell type or
even specific to Htt. The Sup35 PrD, NM, not only suppresses
polyQ-expanded Htt exon-1 toxicity in yeast and human cells as
shown in this report but also suppresses polyQ-expanded SCA3
toxicity in Drosophila (43). As noted above, interaction between
Q-rich proteins and polyQ-expanded disease proteins frequently
leads to enhanced toxicity, but clearly, there are examples of
beneficial interactions like those reported here in yeast and
previously in C. elegans (44). No doubt the phenotypic outcome
will depend on the expression patterns of the Q-rich proteins, as
well as their posttranslational modifications, in the context of
a particular proteome. Variability in this interaction network
must be a key contributor to the vulnerability of different cell
types to different polyQ expansion proteins. The complexity of
these effects is daunting. Nevertheless, learning to control these
interactions might prove a valuable strategy in the treatment of
polyQ expansion diseases.
Materials and Methods
Overexpression Screen and PrD Modifiers. The overexpression library consisted
of 5,532 full-length, untagged, sequence-verified, galactose-inducible yeast
ORFs in the plasmid pBY001 in a BY4741 yeast strain (14). PrD modifiers were
cloned into Gateway destination vectors with C-terminal fluorescent fusion
proteins and transformed into the BY4741 strain. These strains were in-
dividually mated with a [RNQ+] w303 strain containing Htt103Q integrations
of pRS303GAL-FLAG-Htt103Q-ECFP and pRS305GAL-FLAG-Htt103Q-DsRed
(see SI Materials and Methods for more details).
HEK-293 Assays. Approximately 200 EGFP-Htt72Q and PrD-mCherry express-
ing cells were counted per modifier and assessed for cell death and aggre-
gation. Nuclei were stained with 4′,6-diamidino-2-phenylindole, and those
that showed morphology indicative of necrosis or apoptosis (for example,
fragmentation or pyknosis) were considered dead. Each experiment was
carried out in triplicate and performed at least twice. Thus, cell death and
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Fig. 5. Dynamics of Htt103Q foci. (A) FRAP traces of Htt103Q in foci (dashed
line) and outside of foci (solid line) in cells expressing Htt103Q and the
suppressor NM. (B) Brightness of Htt103Q-ECFP particles in lysates of cells
expressing mCherry-tagged PrD modifiers or a neutral control (free EYFP).
The brightness of free ECFP monomers is indicated by the dotted line.
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aggregation are expressed in terms of odds ratio (see SI Materials and
Methods for more details).
Epifluorescence, Time Lapse, and Confocal Imaging. For epifluorescence imag-
ing, we used the original screening strain described above with EYFP-tagged
PrD modifiers. The ECFP-tagged Htt103Q protein proved superior for fluores-
cence microscopy and was used as a general indicator of the fate of Htt103Q
in our yeast cells. Cells were grown overnight in liquid culture, and images
were acquired with a Nikon Plan Apo 100× oil objective (NA 1.4). Data from two
biological replicates for enhancers and three for suppressors were quantitated.
The strains used for time-lapse and confocal imaging experiments were
identical except that allmodifiers were integrated into the genomeat theURA
locus. VHL was tagged with EYFP and expressed from a galactose-inducible
vector integrated in the URA locus. Rnq1 and NHP6a were both endoge-
nously tagged with iRFP. For time-lapse imaging, mKate2 was integrated into
the HO locus to serve as a cytoplasmic marker. Time-lapse bright field and RFP
images were captured every 15 min, and CFP and YFP channels were acquired
every 30 min (see SI Materials and Methods for more details).
High-Content Microscopy. High-content microscopy of SH-EP cells coexpress-
ing EYFP-tagged Htt79Q and mCherry-tagged PrD modifiers was performed
as previously described (20).
FRAP. The Htt103Q strain coexpressing EYFP-tagged PrDmodifiers growing
in log phase was subjected to FRAP on an Andor Revolution spinning disk
confocal microscope using a 100× 1.49 NA Nikon Plan Apo objective. ECFP-
tagged Htt103Q molecules were bleached with a single 405-nm laser
pulse with a dwell time of 600 μs at 15% of maximum power. Recovery
was recorded with 2-s exposures of 405 nm excitation every 5 s. Little or
no additional photobleaching occurred during these acquisitions. Data
were analyzed with EasyFRAP analysis software (45).
FCS. All experiments were performed with the Htt103Q strain coexpressing
mCherry-tagged PrD modifiers. Yeasts were spheroplasted and gently lysed
with 2% Igepal at 4 °C and centrifuged for 30 min at 14,000 × g to remove
large aggregates (see SI Materials and Methods for details).
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